Highlights • Upadacitinib is an effective treatment option for rheumatoid arthritis, but whether its use confers digestive event risk remains unclear. • Our meta-analysis showed that there was no increased risk of hepatic disorder and gastrointestinal perforation (GIP) with upadacitinib. • We observed that dose dependency had no increasing risk for digestive events in upadacitinib in various subgroup analyses.
All Keywords
【저자키워드】 rheumatoid arthritis, gastrointestinal perforation, Upadacitinib, Hepatic disorder,
【저자키워드】 rheumatoid arthritis, gastrointestinal perforation, Upadacitinib, Hepatic disorder,